

# Benjamin G Carlisle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1904461/publications.pdf>

Version: 2024-02-01

16  
papers

479  
citations

1162367

8  
h-index

940134

16  
g-index

24  
all docs

24  
docs citations

24  
times ranked

831  
citing authors

#	ARTICLE	IF	CITATIONS
1	How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov. PLoS ONE, 2022, 17, e0262114.	1.1	7
2	Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers. Clinical Trials, 2022, 19, 337-346.	0.7	6
3	Analysis of clinical trial registry entry histories using the novel R package cthist. PLoS ONE, 2022, 17, e0270909.	1.1	6
4	Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. JAMA Network Open, 2021, 4, e2110456.	2.8	10
5	Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials, 2020, 17, 18-29.	0.7	5
6	Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute, 2020, 112, 859-862.	3.0	2
7	Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology, 2020, 17, 1-3.	12.5	24
8	Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. BMJ Open, 2020, 10, e034306.	0.8	6
9	How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?. International Journal of Cancer, 2019, 145, 3370-3375.	2.3	4
10	Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval. BMJ: British Medical Journal, 2018, 360, k959.	2.4	14
11	Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. JAMA - Journal of the American Medical Association, 2017, 318, 1003.	3.8	8
12	Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biology, 2017, 15, e2000487.	2.6	33
13	Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. Journal of the National Cancer Institute, 2016, 108, .	3.0	46
14	Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ, The, 2015, 350, h1116-h1116.	3.0	26
15	Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clinical Trials, 2015, 12, 77-83.	0.7	244
16	Rethinking Research Ethics: The Case of Postmarketing Trials. Science, 2012, 336, 544-545.	6.0	32